Search Results for “diabetes” – Page 6 – media

New Anti-Diabetes Drug Aids In Weight Loss

U.S. Food and Drug Administration officially approved the weekly injection of semaglutide under the brand name of Ozempic. This therapy along with healthy diet and exercise would improve glycemic control in adults with type 2 diabetes. The side effects of semaglutide was found to be mild or moderate nausea.
- Source: India Times
- 758
- June 14, 2018
diabetes New Approvals obesity
Glooko Launched Advanced Version for Diabetes Management

The newly launched site will also provide details on the effect that food intake, exercise, and medication can have on control glucose levels along with color-coded graph and charts which are focused at usability, bolus tracking features, amplified insulin pump reports, and statistics.
- Source: MobiHealthNews
- 724
- June 12, 2018
diabetes mHealth New Approvals
New Drug Shows Excellent Improvement for Oral Diabetes Meds

Denmark-based, Novo Nordisk developed a drug that stimulates insulin productions called semaglutide a class of drugs which categorized in GLP-1s. The new oral diabetes medicine is a better lowering blood sugar levels compared to the existing drug.
- Source: Ddu
- 1,359
- May 31, 2018
Diabetes Drugs New Approvals Novo Nordisk
Smartphone apps to help Queensland mothers from gestational diabetes

Diabetes Australia's (the third oldest diabetes association in the world) latest figures show that over 200,000 women have suffered gestational diabetes during the last 10 years and is expected to exceed 500,000 within the next decade. Gestational diabetes can be fatal if untreated and could likely lead to overweight babies, premature births, as well as PreEclampsia.
- Source: Ddu
- 864
- May 11, 2018
diabetes pregnancy Researches
Lilly and China’s NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease

Collaboration between China's National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China - The Lilly and NCCD collaboration will address four strategic areas to advance scientific understanding and medical education related to diabetes and cardiovascular disease
- Source: prnewswire
- 525
- April 26, 2018
Company Insights CVD Eli Lilly NCCD
Artificial pancreas is a safe and effective treatment for type 1 diabetes

Use of an artificial pancreas is associated with better control of blood sugar levels for people with type 1 diabetes compared with standard treatment, finds a review of the available evidence published by The BMJ today.
- Source: MedicalXpress
- 627
- April 19, 2018
diabetes digital health Researches
ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes

First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.
- Source: Pipelinereview
- 512
- April 13, 2018
New Approvals type 2 diabetes
Lilly, Sigilon Partner on Encapsulated Cell Therapies for Diabetes

Eli Lilly and Company and Sigilon Therapeutics, a privately held biopharmaceutical company, announced a global collaboration to develop encapsulated cell therapies for potentially treating Type 1 diabetes. The deal is worth up to $473 million. Sigilon is focused on discovering and developing “living therapeutics” using its Afibromer technology product platform.
- Source: Sigilon Therapeutics
- 505
- April 10, 2018
diabetes Market Views
EMA to review sotagliflozin as potential treatment for type 1 diabetes

The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for sotagliflozin. If approved, the oral treatment would be used as an addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus.
- Source: mediaroom.sanofi
- 572
- April 2, 2018
diabetes New Approvals sotagliflozin
Siren launches smart sock for diabetes patients, announces $3.4M in funding

The company, which was founded in 2015, also announced that it has raised $3.4 million in seed funding, from DCM, Khosla Ventures, and Founders Fund.
- Source: Mobile Health News
- 638
- April 2, 2018
Company Insights diabetes digital health mHealth

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.